Philadelphia, Pennsylvania, United States
Contact Info
168 followers
114 connections
Philadelphia, Pennsylvania, United States
Contact Info
168 followers
114 connections
About
Over 25 years of clinical development experience in multiple therapeutic areas, including…
Activity
-
I am happy to share that I have started a new position as Vice President Clinical Development at Cabaletta Bio
I am happy to share that I have started a new position as Vice President Clinical Development at Cabaletta Bio
Liked by David J. Chang, MD, MPH, FACR
-
Cabaletta Bio is attending the Myasthenia Gravis Foundation of America (MGFA) 2024 National Patient Conference in Tampa, FL! Come see us at booth 17…
Cabaletta Bio is attending the Myasthenia Gravis Foundation of America (MGFA) 2024 National Patient Conference in Tampa, FL! Come see us at booth 17…
Liked by David J. Chang, MD, MPH, FACR
Experience & Education
More activity by David J.
-
Dr. Gwendolyn Binder PhD, President of Science and Technology at Cabaletta Bio, will be delivering the opening keynote presentation at the 7th annual…
Dr. Gwendolyn Binder PhD, President of Science and Technology at Cabaletta Bio, will be delivering the opening keynote presentation at the 7th annual…
Liked by David J. Chang, MD, MPH, FACR
-
Cabaletta Bio is excited to announce that CABA-201 has been granted additional Fast Track Designations beyond SLE and lupus nephritis from the FDA -…
Cabaletta Bio is excited to announce that CABA-201 has been granted additional Fast Track Designations beyond SLE and lupus nephritis from the FDA -…
Liked by David J. Chang, MD, MPH, FACR
-
Cabaletta Bio had a great week at #JPM24! Check out CEO Steven Nichtberger, MD's presentation where we review the exciting year ahead that we believe…
Cabaletta Bio had a great week at #JPM24! Check out CEO Steven Nichtberger, MD's presentation where we review the exciting year ahead that we believe…
Liked by David J. Chang, MD, MPH, FACR
-
We are excited to share that we are now recruiting individuals with myositis for our Phase 1/2 study to evaluate the safety and efficacy of CABA-201,…
We are excited to share that we are now recruiting individuals with myositis for our Phase 1/2 study to evaluate the safety and efficacy of CABA-201,…
Liked by David J. Chang, MD, MPH, FACR
-
Cabaletta Bio is pleased to announce that the FDA has granted Fast Track Designation to evaluate the potential for CABA-201 to deplete CD19-positive…
Cabaletta Bio is pleased to announce that the FDA has granted Fast Track Designation to evaluate the potential for CABA-201 to deplete CD19-positive…
Liked by David J. Chang, MD, MPH, FACR
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More